NICE guidance on omalizumab for severe asthma

Lancet Respir Med. 2013 May;1(3):189-90. doi: 10.1016/S2213-2600(13)70066-3. Epub 2013 Apr 24.

Authors

Richard A Diaz¹, Zoe Charles¹, Elisabeth George¹, Amanda I Adler¹

Affiliation

¹ National Institute for Health and Care Excellence, London, UK.

PMID: 24429120
DOI: 10.1016/S2213-2600(13)70066-3

No abstract available

Publication types

News

MeSH terms

Adolescent
Adult
Anti-Asthmatic Agents / economics
Anti-Asthmatic Agents / pharmacology
Antibodies, Anti-Idiotypic* / economics
Antibodies, Anti-Idiotypic* / pharmacology
Antibodies, Monoclonal, Humanized* / economics
Antibodies, Monoclonal, Humanized* / pharmacology
Asthma / drug therapy*
Asthma / etiology
Asthma / physiopathology
Child
Drug Approval
Drug Costs
Humans
Omalizumab
Practice Guidelines as Topic
Respiratory Hypersensitivity / complications*
Severity of Illness Index
Treatment Outcome
United Kingdom

Substances

Anti-Asthmatic Agents
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal, Humanized
Omalizumab

Supplementary concepts

Ige Responsiveness, Atopic